Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RNAZ 1.72 + 30% going quicker then expected 2.16 next line of combat
NVAX maybe ..but $12 max justifies new market cap …Under the agreement, Novavax will get an upfront payment of $500 million and up to $700 million .
Let’s say at $10 1 billion and $12 1.2 billion. At $5 market cap about $500m
Some more short squeezing maybe but always risk involved
RNAZ 1.59 + 16% slow and steady to $2s next week fine with me ..
EFTR see how long it churns between 2.05- 2.25
NVAX 10.77 watch next 11.55 12.29 then 16.30 to 25.04. That’s my imo. Gap between 12.29 and 16.30
NVAX $13s was scalp time. Kept 10% of low $9s see what happens
RNAZ 1.50 + 12% chop chop little resistance up until low $2s take its time is better was a $300 stock … :)
RNAZ 1.43 + 7% otw to $2 resistance slowly
WISA $3.55 SOUN $5s now NVDA backing
10:40 AM EDT, 04/18/2024 (MT Newswires) -- WiSA Technologies (WISA) shares fell more than 26% in recent Thursday trading after the company announced a $750,000 registered direct offering.
The company said it agreed to sell 225,834 of its common shares at $3.321 per share and warrants to buy up to 225,834 common shares at an exercise price of $3.196 per share to certain purchasers. The warrants are set to expire in five years.
The offerings are scheduled to close on Friday, the company added.
NVAX $11.21 + 150% is a zone $18-$25 could possibly hit but another one that was trading at $300 not long ago
NVAX $13.88 + 200% time to exit scalp ..
wards
Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties
Novavax is entitled to additional launch and sales milestone opportunities of up to $200 million, plus mid-single digit royalties, for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M™ adjuvant technology
Accelerates potential for development of a novel COVID-19-Influenza combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering individuals enhanced convenience and protection
GAITHERSBURG, Md., May 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi (Nasdaq: SNY).
The terms of the agreement include: a co-exclusive license to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan and South Korea where Novavax has existing partnership agreements); a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines while Novavax retains the right to and is developing its own COVID-19-Influenza Combination vaccine candidate; a non-exclusive license to use Novavax's adjuvanted COVID-19 vaccine for use in combination with non-flu vaccines; and a non-exclusive license to use the Matrix-M adjuvant in vaccine products. In addition, Sanofi will take a minority (<5%) equity investment in Novavax.
"With flu and COVID-19 hospital admission rates now closely mirroring each other, we have an opportunity to develop non-mRNA flu-COVID-19 combination vaccines, offering patients both enhanced convenience and protection against two serious respiratory viruses," said Jean-Francois Toussaint, Global Head of Vaccines R&D, Sanofi. "We're excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines that have demonstrated superior protection against flu and its serious complications. Improved tolerability and thermostability, without compromise on efficacy, are what regulators, recommending bodies and patients will demand."
"This collaboration is important for Novavax and for global public health. Our new partnership combines Novavax's proprietary recombinant protein and nanoparticle technologies, Matrix™ adjuvant and R&D expertise with Sanofi's world-class leadership in launching and commercializing innovative vaccines. Together, we can broaden access to both our COVID-19 vaccine and our adjuvant to ensure more individuals can benefit from the protection vaccines can provide," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Novavax is now in a stronger position to refocus our efforts on leveraging our technology platform and novel adjuvant in R&D and pipeline expansion to help advance our mission of developing life-saving vaccines to fight infectious diseases."
Under the terms of the licensing agreement:
Novavax will receive an upfront payment of $500 million and up to $700 million in development, regulatory and launch milestones, up to $1.2 billion in total.
Starting in 2025, Sanofi will book sales of Novavax's adjuvanted COVID-19 vaccine and will support certain R&D, regulatory and commercial expenses.
Novavax will receive tiered double-digit percentage royalty payments on sales by Sanofi of COVID-19 vaccines and COVID-19-Influenza Combination vaccines.
Sanofi will be solely responsible for development and commercialization of any novel flu-COVID-19 combination vaccine containing a Sanofi flu vaccine.
Outside of the collaboration, each party may develop and commercialize their own COVID-19-Influenza combination vaccines and adjuvanted products at their own cost.
Novavax is entitled to additional launch and sales milestone opportunities of up to $200 million, plus mid-single digit royalties for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M adjuvant technology.
In addition, Sanofi will take a minority (<5%) equity investment in Novavax.
PJT Partners is acting as the exclusive financial advisor to Novavax. Ropes & Gray LLP is serving as legal advisor.
RNAZ $2.16 up next so much dilution on this one was a $300 stock. Traders dream
beaten down garbage.
NVAX morning pump
Good all LIDR cash out rinse repeat. VHAI so diluted at .13 will give you a 100% eventually to .30s. Scalp them don’t fall in love and if you have some houses money after the scalp risk it if so desired
Looking good Calls .check MSOX CGC TLRY ACB etc. looks like this is a better zone
SGD VERI WBUY running
INBS 2.96 + 20% nice tiny float look at 3.04- 3.26 first then 3.38 to 3.62
RNAZ 1.08 time to exit was here .. RNAZ 1.03…. Earlier RNAZ .92 +’13% look for 1.09
RNAZ 1.03…. Earlier RNAZ .92 +’13% look for 1.09 again
RNAZ 1.01 hod
RWOD 11.04 +50% 80% out 10.06
TVTX $7.46 + 13% Looks good Canaccord Genuity $15 buy target. Once it breaks 9.83 on the way to $13. Probably take a few weeks and positive catalysts
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe. Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study.
7.46 + 13% Looks good Caanacord $15 buy target. Once it breaks 9.83 on the way to $13. Probably take a few weeks and positive catalysts
RWOD 8.53 halted again
RWOD 8.16
RWOD 7.74
RWOD 7.30 + 15% tiny float .. halted did some jumping up back down ..older news …NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases. This intellectual property was licensed by ANEW from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain on an exclusive worldwide basis and ANEW paid for all patent costs associated with obtaining –the patent.
Hold $7- 7.42 let’s see if it’s stays up.. NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases. This intellectual property was licensed by ANEW from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain on an exclusive worldwide basis and ANEW paid for all patent costs associated with obtaining –the patent.
Durolane like it .. older news ..Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
Source: GlobeNewswire Inc.
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.
OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE, help manage knee OA pain.
“We are pleased DUROLANE is among the preferred options available to both Aetna™ Medicare Advantage members and physicians,” said Anthony Doyle, General Manager, Pain Treatments and Restorative Therapies for Bioventus. “Both now have access to a safe HA product that is proven to provide relief from knee OA pain.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
EFTR 2.11 see if 2.07-2.13 holds if not buy up the 1.90s dip further down 1.70- 1.81 the ultimate dip zone
Sorry to hear about AGRI stocks under .50 typically scalp for the most part. That’s just me. How bout those rate cuts coming lol. Fully loaded TMF at $43- $44 that support held well at $48 as markets demand lower and lower or that real estate market or dems chance of rel election would go down the toilet
RNAZ .94
RNAZ .92 +’13% look for 1.09 again
GSUN if it can pass 7.40 hard then $10 is next for those still in it. All out myself
GSUN 7.25 + 135% the sun is bright. Time to cash out and don’t look back
The sun is shinning GSUN 4.54 +’56% post rs
CMND getting high again
Naked shorting manipulation that’s how the Big guys take care of retail traders..lol
A combined $40 Million fine to Credit Suisse and Nomura for illegal short selling.."about half the amount of naked short selling transactions"
While the fines have proven not to stop illegal behavior, the last lines of this article suggests these fines are a polite warning to global banks to knock it off or face harsher penalties. (Keep reading)
Remember - HSBC and three traders have been criminally charged with naked short selling in South Korea.
"...According to the FSS, most of the naked short selling appeared to have been conducted due to insufficient internal controls, or the lack of relevant system.
As examples, they placed sell orders before fixing the number of stocks they needed to borrow for shorting, or made calculation errors while shorting stocks.
But the regulatory body said it will no more take them as simple mistakes..."
https://kedglobal.com/markets/newsView/ked202405070006
NYC ESPR
NYC
American Strategic.
7.81
+1.77
+29.30%
ESPR
Esperion
2.73
+0.610
+28.77%
AIRE FGEN TCBP ZETA AMBC EVTL WINT HIMS UMAC OLB
AIRE
reAlpha Tech Corp
1.3600
+0.5035
+58.79%
FGEN
FibroGen Inc
1.50
+0.340
+29.31%
TCBP
TC BioPharm Holdin.
1.77
+0.3200
+22.07%
ZETA
Zeta Global Holdin.
15.750
+2.760
+21.25%
AMBC
Ambac
18.00
+2.88
+19.05%
EVTL
Vertical Aerospace
0.900
+0.132
+17.19%
WINT
Windtree Therapeut.
5.700
+0.820
+16.80%
HIMS
Hims Hers Health
13.48
+1.83
+15.71%
UMAC
Unusual Machines
1.350
+0.180
+15.38%
OLB
OLB Group Inc
4.490
+0.570
+14.54%